Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 1/20 | 0.36 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.36 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23516831 | 0.94 | GRIN2D (0.33) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 | |
| SCHEMBL19507323 | 0.88 | GRIN2D (0.31) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 | |
| SCHEMBL29191147 | 0.82 | GRIN2D (0.35) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 | |
| SCHEMBL3640640 | 0.82 | GRIN2D (0.39) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 | |
| SCHEMBL29021035 | 0.79 | GRIN2D (0.33) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 | |
| SCHEMBL24928071 | 0.78 | CRHBP (0.32) | — | |
| SCHEMBL21754626 | 0.77 | — | — | |
| SCHEMBL27024963 | 0.76 | — | — | |
| SCHEMBL13262669 | 0.76 | CHRM2 (0.32) | CHRM2 | |
| SCHEMBL5663918 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018162-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20200276180-A1 | POLYCYCLIC COMPOUND ACTING AS IDO INHIBITOR AND/OR IDO-HDAC DUAL INHIBITOR | HANGZHOU INNOGATE PHARMA CO., LTD (CN) | 2020-09-03 | — | — | US | disclosed |
| US-20190119295-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200276180-A1 | POLYCYCLIC COMPOUND ACTING AS IDO INHIBITOR AND/OR IDO-HDAC DUAL INHIBITOR | IDO1, HDAC1, HDAC2 | GRIN2D 2282/4885GRIN3B 2442/4885CHRM2 4603/4885 |
| US-20190119295-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | GRIN2D 4750/4885GRIN3B 4131/4885CHRM2 4703/4885 |
| US-20240018162-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | TTK, HIPK1, CLK1 | GRIN2D 4638/4885GRIN3B 4271/4885CHRM2 4833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.